Literature DB >> 20176893

Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.

Yu-Ping Wang1, Fei Liu, Hong-Wei He, Yan-Xin Han, Zong-Gen Peng, Bao-Wei Li, Xue-Fu You, Dan-Qing Song, Zhuo-Rong Li, Li-Yan Yu, Shan Cen, Bin Hong, Chen-Heng Sun, Li-Xun Zhao, Barry Kreiswirth, David Perlin, Rong-Guang Shao, Jian-Dong Jiang.   

Abstract

Heat stress cognate 70 (Hsc70) is a host protein associated with hepatitis B virus (HBV) replication. The goal of this study was to investigate whether Hsc70 could be an anti-HBV drug target. Our results showed that introducing Hsc70 increased HBV replication in HBV(+) human hepatocytes (HepG2.2.15 cells). The coiled-coil region on Hsc70 (nucleotides 1533 to 1608; amino acids 511 to 536) was the key sequence for HBV replication. Knockdown of Hsc70 expression by RNA interference (RNAi) largely inhibited HBV replication with no cytotoxicity to the host. Using an Hsc70 mRNA screening assay, the natural compound oxymatrine (OMTR) was found to be a selective inhibitor for Hsc70 expression. Then, OMTR was used to investigate the potential of Hsc70 as an anti-HBV drug target. OMTR inhibited Hsc70 mRNA expression by 80% and HBV DNA replication by over 60% without causing cytotoxicity. The anti-HBV effect of OMTR appeared to be mediated by destabilizing Hsc70 mRNA. The half-life (T(1/2)) of Hsc70 mRNA decreased by 50% in OMTR-treated hepatocytes. The Hsc70 mRNA 3'-untranslated-region (UTR) sequence was the element responsible for OMTR's destabilization activity. OMTR suppressed HBV de novo synthesis at the reverse transcription stage from pregenomic RNA (pgRNA) to DNA and was active against either wild-type HBV or strains resistant to lamivudine, adefovir, and entecavir. Therefore, host Hsc70 could be a novel drug target against HBV, and OMTR appears to inhibit HBV replication by destabilizing Hsc70 mRNA. As the target is not a viral protein, OMTR is active for either wild-type HBV or strains resistant to reverse transcriptase (RT) inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20176893      PMCID: PMC2863598          DOI: 10.1128/AAC.01764-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Prevention and management of drug resistance for antihepatitis B treatment.

Authors:  Man-Fung Yuen; James Fung; Danny Ka-Ho Wong; Ching-Lung Lai
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

2.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

3.  Fidelity of HIV-1 reverse transcriptase.

Authors:  B D Preston; B J Poiesz; L A Loeb
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

4.  Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine.

Authors:  P M Price; R Banerjee; G Acs
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

5.  Identification of novel nuclear export and nuclear localization-related signals in human heat shock cognate protein 70.

Authors:  Fujiko Tsukahara; Yoshiro Maru
Journal:  J Biol Chem       Date:  2003-12-18       Impact factor: 5.157

6.  Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner.

Authors:  Zhensheng Zhang; Ulrike Protzer; Zongyi Hu; James Jacob; T Jake Liang
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein.

Authors:  Jürgen Beck; Michael Nassal
Journal:  J Biol Chem       Date:  2003-07-08       Impact factor: 5.157

8.  Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; Mo-Bin Wan; Cheng-Zhong Li; Cheng-Wei Chen; Qing-Chun Fu; Ji-Yao Wang; Wei-Min She; Xiong Cai; Jun Ye; Xia-Qiu Zhou; Hui Wang; Shan-Ming Wu; Mei-Fang Tang; Jin-Shui Zhu; Wei-Xiong Chen; Hui-Quan Zhang
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 9.  Viral hepatitis B.

Authors:  Ching Lung Lai; Vlad Ratziu; Man-Fung Yuen; Thierry Poynard
Journal:  Lancet       Date:  2003-12-20       Impact factor: 79.321

10.  Lipid interaction differentiates the constitutive and stress-induced heat shock proteins Hsc70 and Hsp70.

Authors:  Nelson Arispe; Michael Doh; Antonio De Maio
Journal:  Cell Stress Chaperones       Date:  2002-10       Impact factor: 3.667

View more
  17 in total

1.  Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators.

Authors:  Donna M Huryn; Jeffrey L Brodsky; Kay M Brummond; Peter G Chambers; Benjamin Eyer; Alex W Ireland; Masaoki Kawasumi; Matthew G Laporte; Kayla Lloyd; Baptiste Manteau; Paul Nghiem; Bettina Quade; Sandlin P Seguin; Peter Wipf
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

Review 2.  HBV replication inhibitors.

Authors:  Claire Pierra Rouviere; Cyril B Dousson; John E Tavis
Journal:  Antiviral Res       Date:  2020-05-05       Impact factor: 5.970

Review 3.  Host factors involved in hepatitis B virus maturation, assembly, and egress.

Authors:  Reinhild Prange
Journal:  Med Microbiol Immunol       Date:  2012-09-11       Impact factor: 3.402

4.  Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines.

Authors:  Zhikui Cheng; Ge Sun; Wei Guo; Yayun Huang; Weihua Sun; Fei Zhao; Kanghong Hu
Journal:  Virol Sin       Date:  2015-08-08       Impact factor: 4.327

5.  Host APOBEC3G protein inhibits HCV replication through direct binding at NS3.

Authors:  Yan-Ping Zhu; Zong-Gen Peng; Zhou-Yi Wu; Jian-Rui Li; Meng-Hao Huang; Shu-Yi Si; Jian-Dong Jiang
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 6.  The sterile inflammation in the exacerbation of HBV-associated liver injury.

Authors:  Qiao Yang; Yu Shi; Ying Yang; Guohua Lou; Zhi Chen
Journal:  Mediators Inflamm       Date:  2015-03-29       Impact factor: 4.711

7.  Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70.

Authors:  Zhongqi Bian; An Xiao; Mingmei Cao; Mingqiu Liu; Shuang Liu; Ye Jiao; Weiyao Yan; Zhongtian Qi; Zhaoxin Zheng
Journal:  Virol J       Date:  2012-11-16       Impact factor: 4.099

Review 8.  Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.

Authors:  Lei Kang; Jiaqian Pan; Jiaofen Wu; Jiali Hu; Qian Sun; Jing Tang
Journal:  Viruses       Date:  2015-09-15       Impact factor: 5.048

Review 9.  The Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-Analysis.

Authors:  Min He; Yu Wu; Mengmeng Wang; Wenwen Chen; Weian Yuan; Jian Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-05       Impact factor: 2.629

10.  Oxymatrine Inhibits Proliferation and Migration While Inducing Apoptosis in Human Glioblastoma Cells.

Authors:  Feili Liu; Baocheng Wang; Jiajia Wang; Xiaozheng Ling; Qifeng Li; Wei Meng; Jie Ma
Journal:  Biomed Res Int       Date:  2016-11-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.